Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

17 trials with published results (20%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.7%

5 terminated out of 87 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

23%

20 trials in Phase 3/4

Results Transparency

34%

17 of 50 completed with results

Key Signals

17 with results91% success

Data Visualizations

Phase Distribution

72Total
Not Applicable (9)
Early P 1 (1)
P 1 (31)
P 2 (11)
P 3 (9)
P 4 (11)

Trial Status

Completed50
Unknown14
Active Not Recruiting8
Terminated5
Not Yet Recruiting4
Recruiting4

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 50 completed trials

Clinical Trials (87)

Showing 20 of 20 trials
NCT05676645Active Not RecruitingPrimary

Pharmacokinetics of Antimalarials in Breastfeeding Ugandan Mother-infant Pairs

NCT06558643Phase 1CompletedPrimary

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

NCT06320535Phase 1Active Not RecruitingPrimary

A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™

NCT07183371Phase 2Active Not RecruitingPrimary

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

NCT06958198Phase 1RecruitingPrimary

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

NCT05567016Not ApplicableCompletedPrimary

CHILD (Child Health and Infection With Low Density) Malaria

NCT06413108Phase 1CompletedPrimary

Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali

NCT05757167Phase 4RecruitingPrimary

Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics

NCT05979207Phase 1Completed

Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum

NCT06618885Phase 1Active Not RecruitingPrimary

Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso

NCT06083688Phase 4Active Not RecruitingPrimary

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

NCT07009847RecruitingPrimary

An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine

NCT03896724Phase 1CompletedPrimary

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

NCT05878366Not ApplicableCompleted

Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC)

NCT05252845Phase 2CompletedPrimary

Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults

NCT05287893Phase 1CompletedPrimary

Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria

NCT05790889Phase 1RecruitingPrimary

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

NCT04862416Phase 1Completed

Safety and Efficacy of R0.6C Vaccine

NCT03947190Phase 2TerminatedPrimary

A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

NCT05507970Phase 1CompletedPrimary

First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367

Scroll to load more

Research Network

Activity Timeline